Capiri | 1100690-10-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: Capiri
• 英文别名: [(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate;pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
• CAS: 1100690-10-5
• 化学式: C48H60FN7O12
• 分子量: 946.0
• InChiKey: PGMBSCDPACPRSG-SCSDYSBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.85
• 重原子数：
  68
• 可旋转键数：
  12
• 环数：
  9.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  233
• 氢给体数：
  4
• 氢受体数：
  15

文献信息

• METHOD FOR TREATING ABNORMAL CELL GROWTH
  申请人：Pfizer Products Incorporated

  公开号：EP1761281A1

  公开（公告）日：2007-03-14
• GENOTYP- BZW. PHÄNOTYP-BASIERTE ARZEIMITTELFORMULIERUNGEN
  申请人：Bayer Technology Services GmbH

  公开号：EP2854789A1

  公开（公告）日：2015-04-08
• [EN] METHOD FOR TREATING ABNORMAL CELL GROWTH<br/>[FR] TECHNIQUE DE TRAITEMENT DE CROISSANCE CELLULAIRE ANORMALE
  申请人：PFIZER PROD INC

  公开号：WO2005115391A1

  公开（公告）日：2005-12-08

  Therapeutic pharmaceutical compositions and methods of treatment of abnormal cell growth comprising a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof in combination with an oral camptothecin, an oral camptothecin derivative, an indolopyrrocarbazole derivative or a pharmaceutically acceptable salt, solvate or prodrug thereof for the treatment of cancer are described. In one embodiment of the present invention the oral camptothecin derivative is selected from the group consisting of 10-­hydroxycamptothecin, 9-aminocamptothecin, 9-nitrocamptothecin, irinotecan, irinotecan salt, SN-38, CPT-11, and topotecan and the indolopyrrocarbazole derivative is edotecarin. In one embodiment the pyrimidine derivative is selected from the group consisting gemcitabine, MTA and capecitabine. In one preferred embodiment, the pyrimidine derivative is capecitabine and the camptothecin derivative is CPT-11.
• [EN] METHOD FOR TREATING ABNORMAL CELL GROWTH<br/>[FR] METHODE DE TRAITEMENT DE CROISSANCES CELLULAIRES ANORMALES
  申请人：PFIZER PROD INC

  公开号：WO2005117980A1

  公开（公告）日：2005-12-15

  The present Invention relates to a method of treating abnormal cell growth in a subject, comprising administering to said subject having abnormal cell growth: (a) a compound selected from the group consisting of a camptothecin, a camptothecin derivative, or a pharmaceutically acceptable salt, solvate or prodrug of said compounds; (b) a pyrimidine derivative or a pharmaceutically acceptable salt, solvate or prodrug of said pyrimidine derivative; and (c) an anti-tumor agent selected from the group consisting of antiproliferative agents, kinase inhibitors, angiogenesis inhibitors, growth factor inhibitors, cox-I inhibitors, cox­-II inhibitors, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, radiation, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, anti-androgens and combinations thereof.
• [DE] GENOTYP- BZW. PHÄNOTYP-BASIERTE ARZEIMITTELFORMULIERUNGEN<br/>[EN] GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION<br/>[FR] COMPOSITIONS MÉDICAMENTEUSES BASÉES SUR UN GÉNOTYPE OU UN PHÉNOTYPE
  申请人：BAYER TECHNOLOGY SERVICES GMBH

  公开号：WO2013178565A1

  公开（公告）日：2013-12-05

  Die Erfindung betrifft eine Kombination aus zweien oder mehreren pharmazeutisch aktiven Substanzen, von denen mindestens eine ein Stoffwechselprodukt („Metabolit") der anderen („Muttersubstanz") ist, insbesondere wobei deren Dosierungen derart gewählt werden, dass eine geno- bzw. phänotypisch bedingte Variabilität der Umsetzung der Muttersubstanz zu dem Metaboliten in bestimmten Individuen kompensiert wird.